@article{ceed6b6622e94ebab18fccad83ccf4eb,
title = "No association between omalizumab use and risk of cancer: a nationwide registry-based cohort study",
author = "Zarqa Ali and Alexander Egeberg and Thyssen, \{Jacob P.\} and S{\o}rensen, \{Jennifer Astrup\} and Christian Vestergaard and Thomsen, \{Simon Francis\}",
note = "Funding Information: Conflicts of interest: with no relation to the current work, A.E. has received research funding from Pfizer, Eli Lilly and Company, Novartis, Bristol Myers Squibb, AbbVie, Janssen Pharmaceuticals, the Danish National Psoriasis Foundation, the Simon Spies Foundation, and the Kgl Hofbundtmager Aage Bang Foundation; and honoraria as consultant and/or speaker from AbbVie, Almirall, LEO Pharma, Zuellig Pharma, Gal{\'a}pagos NV, Sun Pharmaceutical Industries Limited, Samsung Bioepis Co., Ltd., Pfizer, Eli Lilly, Novartis, Galderma, Dermavant Sciences, Inc., UCB, Mylan, Bristol Myers Squibb and Janssen. J.P.T. has attended advisory boards for Eli Lilly, Almirall, Arena Pharmaceuticals, Inc., Pfizer, AbbVie, LEO Pharma, Regeneron and Sanofi Genzyme, been an investigator for LEO Pharma, Sanofi Genzyme, Eli Lilly, AbbVie and Pfizer, and received speaker honoraria from LEO Pharma, Pfizer, Almirall, AbbVie, Eli Lilly, Regeneron and Sanofi‐Genzyme. C.V. has been a speaker, investigator and served at advisory boards for and received research grants from Novartis. S.F.T. has been a speaker, investigator, served on advisory boards and received research support from Novartis. Z.A. and J.A.S. declare they have no conflicts of interest. ",
year = "2022",
doi = "10.1111/bjd.20941",
language = "English",
volume = "186",
pages = "746--748",
journal = "British Journal of Dermatology",
issn = "0007-0963",
publisher = "Oxford University Press",
number = "4",
}